GIPR and type 2 diabetes mellitus: Our work demonstrates that tirzepatide indeed exhibits GIPR agonism in the islets of healthy human donors [62]; however, this does not account for the reduction in GIPR sensitivity in patients with T2D or the potential differences in GIPR agonism between islet cells and food-intake regulating neurons.